ALLMedicine™ Lennox-gastaut Syndrome Center

Nov 20th, 2021 - The aim of the current study was to investigate the long-term outcome in a large cohort of patients with Lennox-Gastaut syndrome (LGS). This was a longitudinal study (a retrospective database review with a telephone follow-up interview). All patie...

Nov 15th, 2021 - Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) are rare, treatment-resistant forms of epilepsy characterized by childhood onset of seizures. Cost-effectiveness analysis for new antiseizure medications typically requires health state utilit...

Oct 24th, 2021 - Cannabidiol has been shown to be effective in seizure reduction in patients with Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis. However, very little is known about its potential to reduce interictal epileptiform activity and imp...

Oct 13th, 2021 - Children and young adults with epilepsy had fewer seizures after combination treatment with the drug Epidiolex, which contains the cannabidiol (CBD), and various doses of tetrahydrocannabinol (THC), the component of cannabis that makes people high.

Oct 10th, 2021 - Patients diagnosed with Lennox Gastaut syndrome (LGS), an epileptic encephalopathy characterized by usually drug resistant generalized and focal seizures, are often considered as candidates for vagus nerve stimulation (VNS). Recent research shows ...

Oct 7th, 2021 - A total of 24 subjects are planned: 6 subjects in each of 4 cohorts: Cohort I (≥18 years), Cohort II (12 to <18 years), Cohort III (6 to <12 years), and Cohort IV (2 to <6 years). For Cohorts I and II, PK assessments of carisbamate, S-enantiomer a...

Jul 16th, 2021 - This study attempts to view the effect of Epidiolex on subjects with Electrical Status Epilepticus of Sleep (ESES). ESES can cause various types of seizures which can fluctuate during sleep. Similar studies have been conducted with Epidiolex with ...

Jun 18th, 2021 - This is a two-part, multicenter, double-blind, parallel-group, placebo controlled study to evaluate the effect of ZX008 when used as adjunctive therapy for the treatment of uncontrolled seizures in children and adults with Lennox-Gastaut syndrome ...

Oct 14th, 2020 - This is a multi-center, open-label extension study for participants with Dravet syndrome or Lennox-Gastaut syndrome who have previously participated in double-blind, placebo-controlled clinical studies of GWP42003-P (Core Studies). The first parti...

Aug 6th, 2019 - This study was designed to evaluate the cognitive effect, safety, and pharmacokinetics (PK) of rufinamide on Lennox-Gastaut Syndrome (LGS) inadequately controlled in pediatric participants already taking other anti-epileptic drugs.

Oct 13th, 2021 - Children and young adults with epilepsy had fewer seizures after combination treatment with the drug Epidiolex, which contains the cannabidiol (CBD), and various doses of tetrahydrocannabinol (THC), the component of cannabis that makes people high.

Sep 16th, 2021 - Topical cannabidiol (CBD) gel, added to antiseizure medication, may help reduce seizures and improve quality of life in children with developmental and epileptic encephalopathies, according to the results of a nonrandomized controlled trial. Devel...

Apr 20th, 2021 - At the ongoing Academy of Neurology 2021 Annual Meeting, being held virtually on April 17-22, Joseph Sirven, MD, professor of neurology at the Mayo Clinic in Jacksonville, Florida, led an epilepsy course updating viewers on new epilepsy medication...

Apr 20th, 2021 - The European Commission (EC) has approved cannabidiol (Epidyolex) oral solution as adjunctive treatment of seizures associated with tuberous sclerosis complex (TSC) in patients aged 2 years and older. It's the third indication for the drug in Euro...

Feb 2nd, 2021 - Tetrahydrocannabinol (THC), the psychoactive agent in cannabinoids, may provide an alternative to off-label use of antipsychotics and other medications to manage agitation in patients with Alzheimer's disease (AD), a new clinical review suggests. ...